Use of phosphodiesterase inhibitors for treating multidrug resistance
AssigneeSt. John's University
InventorsZhe-Sheng CHEN, Zhi SHI, Charles R. ASHBY, JR.
Life of this patent
Estimating the term…
Loading patent…
AssigneeSt. John's University
InventorsZhe-Sheng CHEN, Zhi SHI, Charles R. ASHBY, JR.
Estimating the term…
The present invention relates to methods of treating multidrug resistance in cancerous cells with phosphodiesterase (PDE) inhibitors, e.g., PDE5 inhibitors. More specifically, the invention relates to methods of treating multidrug resistance that arises, e.g., during administration of chemotherapeutic/antineoplastic (anticancer) agents for treatment of cancer, with a PDE5 inhibitor (e.g., sildenafil, vardenafil, and tadalafil). The invention also relates to methods of treating cancer, e.g., multidrug resistant cancer, using a PDE5 inhibitor in combination with an antineoplastic therapeutic agent. Further, the invention relates to pharmaceutical compositions for treating multidrug resistant cancers comprising a PDE5 inhibitor, or a combination of a PDE5 inhibitor and an antineoplastic agent.
A method of treating multidrug resistance in a cancer cell in a subject in need thereof by inhibiting ABCB1 transporter activity, comprising administering to the subject a therapeutically effective amount of a phosphodiesterase 5 (PDE5) inhibitor.
A method of treating multidrug resistance in a cancer cell in a subject in need thereof by inhibiting ABCG2 transporter activity, comprising administering to the subject a therapeutically effective amount of a PDE5 inhibitor.
A method of treating multidrug resistance in a cancer cell in a subject in need thereof by inhibiting ABCC10 transporter activity, comprising administering to the subject a therapeutically effective amount of a PDE5 inhibitor.
Dependencies are inferred from the claim text.